펩타이드 약물 복합체(PDC) 시장 규모는 2024년 19억 2,751만 달러에서 예측 기간 동안 28.73%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 138억 4,985만 달러 규모로 성장할 것으로 예상됩니다.
전 세계적으로 암 환자가 증가함에 따라 기존 치료법에 비해 효능이 향상되고 전신 독성이 감소된 표적 치료제로서 펩타이드 약물 복합체(PDC)에 대한 수요가 크게 증가하고 있습니다. 우수한 치료 효과, 생체 적합성, 특정 종양 세포를 표적으로 삼는 능력으로 인해 PDC의 채택이 증가함에 따라 시장 성장을 더욱 가속화하고 있습니다. 또한, 생명공학 기업, 연구기관, 제약회사 간의 전략적 제휴가 증가하면서 혁신을 촉진하고 새로운 PDC의 개발을 촉진하고 있습니다. 현재 진행 중인 제품 개발 활동은 펩타이드 합성 및 접합 기술의 발전과 함께 PDC의 치료 용도를 확대하여 2025년부터 2032년까지의 예측 기간 동안 세계 PDC 시장을 종합적으로 견인할 것으로 예상됩니다.
펩타이드 약물 복합체(PDC) 시장 역학:
국제암연구소(International Agency for Research on Cancer)의 최근 데이터(2024년)에 따르면, 2022년 전 세계에서 새로 발생한 전립선암 환자 수는 147만 명으로 추정되며, 2045년에는 263만 명으로 증가할 것으로 예상됩니다. 증가될 것으로 예상하고 있습니다. 전립선 특이적 막 항원(PSMA)과 결합하도록 설계된 전립선암 표적 PDC는 정상 조직을 보존하면서 암세포에 직접 세포독성 약물을 전달함으로써 치료의 정확도를 크게 향상시킵니다. 이 표적 접근법은 독성을 줄이고 치료 효과를 높입니다. 또한, PDC는 종양 항원 제시를 촉진하여 면역 반응을 자극하고 항암 작용을 강화할 수 있습니다. 또한, 펩타이드 합성 및 접합 기술에 대한 투자 증가와 기술 발전은 차세대 PDC의 개발을 촉진하고 전립선암에 대한 유망한 치료법으로 전립선암에서 PDC 시장의 성장을 가속하고 있습니다.
또한, 같은 자료에 따르면 2022년 호지킨림프종과 비호지킨림프종 등 혈액 악성종양 신규 환자 수는 각각 82,500명과 553,000명이며, 2045년에는 각각 10,900명과 890,000명에 달할 것으로 예측됩니다. 많은 림프종은 CD19나 CD20과 같은 특이적인 표면 마커를 발현하고 있으며, 이들은 펩타이드에 의해 표적이 될 수 있습니다. 이러한 펩타이드에 세포독성 약물을 결합시킴으로써 PDC는 악성 세포에 직접 약물을 전달할 수 있고, 건강한 조직에 대한 손상을 줄이면서 치료 효과를 높일 수 있어 PDC 시장을 촉진할 수 있습니다.
제품별로는 Lutathera(lutetium Lu 177 dotatate)가 2024년 37% 시장 점유율을 차지할 것으로 예상되며, Lutathera는 표적 암 치료, 특히 신경내분비종양(NET)에 대한 획기적인 역할로 전체 PDC 시장을 주도할 것으로 예상됩니다. FDA가 승인한 최초의 방사성 동위원소 표지 소마토스타틴 유사체로서 소마토스타틴 수용체 양성 종양을 표적으로 하는 탁월한 효능을 입증하여 암 치료에 있어 탁월한 효과를 입증한 루타테라의 주요 장점 중 하나는 표적 방사선을 조사하는 능력으로, 기존 화학요법에서 흔히 발생하는 부작용을 최소화하고 기존 화학요법에서 흔히 볼 수 있는 부작용을 줄여줍니다. 루타세라는 소마토스타틴 수용체를 발현하는 종양세포에 특이적으로 결합하여 정상조직의 손상을 최소화하고 환자의 예후와 삶의 질을 개선할 수 있습니다.
지역별로는 북미가 2024년 56.70%의 가장 큰 점유율을 차지할 것으로 예상되며, 예측 기간 동안 28.47%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상되며, PDC 개발을 위한 주요 기업 간의 협력 증가와 PDC 분야에서 신흥국 시장의 발전은 이 지역의 전체 PDC 시장을 더욱 촉진할 것으로 예상됩니다. 더욱 촉진하고 있습니다.
세계의 펩타이드 약물 복합체(PDC) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규제 환경, 시장 규모 추이와 예측, 각종 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Peptide Drug Conjugates Market by Product (Lutathera (lutetium Lu 177 dotatate), Pepaxti (Melphalan flufenamide), and Pluvicto (lutetium Lu 177 vipivotide tetraxetan)), Cancer Type (Prostate Cancer, Gastrointestinal Cancer, Multiple Myeloma), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of cancer worldwide, growing adoption of peptide drug therapeutics owing to superior treatment outcomes and enhanced efficacy, and increase in strategic collaborations and product development activities in the domain of peptide drug conjugates across the globe.
The Peptide Drug Conjugates market was valued at USD 1,927.51 million in 2024, growing at a CAGR of 28.73% during the forecast period from 2025 to 2032 to reach USD 13,849.85 million by 2032. The rising cases of cancer worldwide are significantly driving the demand for Peptide Drug Conjugates (PDCs) as targeted therapies, offering enhanced efficacy and reduced systemic toxicity compared to traditional treatments. The growing adoption of peptide drug therapeutics, owing to their superior treatment outcomes, biocompatibility, and ability to target specific tumor cells, further accelerates market growth. Additionally, increased strategic collaborations between biotech companies, research institutions, and pharmaceutical firms are fostering innovation and expediting the development of novel PDCs. Ongoing product development activities, coupled with advancements in peptide synthesis and conjugation technologies, are expanding the therapeutic applications of PDCs, and collectively boosting the global peptide drug conjugate market during the forecast period from 2025 to 2032.
Peptide Drug Conjugates Market Dynamics:
As per the recent data provided by the International Agency for Research on Cancer (2024), in 2022, globally, the estimated number of new cases of prostate cancer was 1.47 million and the projections were estimated to increase to 2.63 million by 2045. Peptide-drug conjugates, targeting prostate cancer, such as those designed to bind prostate-specific membrane antigen (PSMA), significantly enhance treatment precision by delivering cytotoxic agents directly to cancer cells while sparing normal tissues. This targeted approach reduces toxicity and boosts therapeutic outcomes. Additionally, PDCs can stimulate an immune response by promoting tumor antigen presentation, enhancing their anti-cancer effects. Additionally, increasing pharmaceutical investments and advancements in peptide synthesis and conjugation technologies are driving the development of next-generation PDCs, making them a promising therapy for prostate cancer, and thereby boosting the market growth for peptide drug conjugates in prostate cancer.
Additionally, as per the same source, globally, the estimated new cases of hematological malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma in 2022 were 82,500 and 553,000 respectively and the projections were indicated to reach 10,900 and 890,000 respectively by 2045. Many lymphomas express specific surface markers, such as CD19 and CD20, which can be targeted by peptides. By conjugating cytotoxic agents to these peptides, PDCs can deliver drugs directly to malignant cells, enhancing therapeutic efficacy while reducing damage to healthy tissues and hence boosting the market of PDCs.
However, the increased adoption and superior treatment outcomes with enhanced efficacy of peptide drug conjugates are driving their adoption as promising therapeutic options in oncology. By leveraging the specificity of peptides for targeted delivery, PDCs improve drug accumulation at tumor sites while minimizing systemic toxicity. For instance, a recent study developed a HER2-targeting peptide-drug conjugate (HER2-TPMC) that demonstrated superior specificity and lower cytotoxicity compared to traditional chemotherapeutic agents like mertansine. The smaller size of HER2-TPMC enables rapid tissue penetration and effective tumor uptake, resulting in better therapeutic outcomes.
For instance, in March 2024, ProteinQure, the leading startup in the computational design of peptide drugs, announced a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models.
Thus, the factors mentioned above are expected to boost the overall market of peptide drug conjugates across the globe during the forecast period from 2025 to 2032.
However, limited therapeutic potential on solid tumors low oral bioavailability, and high manufacturing costs and complexity may hinder the future market of peptide drug conjugates across the globe during the forecasted period.
Peptide Drug Conjugates Market Segment Analysis:
Peptide Drug Conjugates Market by Product (Lutathera (lutetium Lu 177 dotatate), Pepaxti (Melphalan flufenamide), and Pluvicto (lutetium Lu 177 vipivotide tetraxetan)), Cancer Type (Prostate Cancer, Gastrointestinal Cancer, Multiple Myeloma), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
The Lutathera (lutetium Lu 177 dotatate) category in the peptide drug conjugates market is estimated to dominate the market with a market share of 37% in 2024. Lutathera is significantly driving the overall market for peptide drug conjugates due to its groundbreaking role in targeted cancer therapy, particularly for neuroendocrine tumors (NETs). As the first FDA-approved radiolabeled somatostatin analog, it has demonstrated exceptional efficacy in targeting somatostatin receptor-positive tumors, a capability that sets it apart in the oncology treatment landscape. One of the key advantages of Lutathera is its ability to deliver targeted radiation, reducing the side effects commonly associated with traditional chemotherapy. By binding specifically to tumor cells expressing somatostatin receptors, Lutathera minimizes damage to normal tissues, which can improve patient outcomes and quality of life.
Furthermore, Lutathera has set a precedent in the growing field of peptide receptor radionuclide therapy (PRRT), sparking further interest in developing other peptide drug conjugates for the treatment of various cancers. For instance, in April 2024, Novartis announced that the FDA approved Lutathera(R) (lutetium Lu 177 dotatate) for treating pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), making it the first therapy approved for pediatric GEP-NETs.
Thus, its success demonstrates the potential of radiopharmaceuticals in targeted therapy and is encouraging to drive continued investment in innovative treatments that combine peptides with radioactive agents for better precision in cancer treatment.
Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of peptide drug conjugates across the globe.
North America is expected to dominate the overall peptide drug conjugates market:
Among all regions, North America is estimated to hold the largest share of 56.70% in the global peptide drug conjugates market in 2024, growing at a CAGR of 28.47% during the forecast period from 2025 to 2032. This can be attributed to the rising cases of cancer in the U.S. Additionally, the increase in collaborations among key players for peptide drug conjugates development, and growing investments in the domain of PDCs are further propelling the overall market of PDCs across the region.
According to the American Cancer Society 2024, nearly 2 million new cancer cases are expected to be diagnosed in the United States by the end of 2024, up from 1.9 million in 2023.
As per the Centers for Disease Control and Prevention (2024), the U.S. cancer statistics recorded 1,777,566 new cases of invasive cancer occurring in 2021; comprising 272,454 breast cancers, 141,902 colorectal cancers, and 209,500 lung cancers reported in 2021. As cancer cases rise, there is a growing demand for innovative therapies that effectively target tumor cells while sparing healthy tissues. PDCs address this need by combining peptides with potent cytotoxic agents, enhancing treatment efficacy and minimizing systemic toxicity.
Additionally, key players in the region are focusing on R&D to develop innovative peptide-drug conjugates. For example, in February 2021, Theratechnologies Inc. announced that the U.S. Food and Drug Administration (FDA) had granted fast-track designation for TH1902, a docetaxel-based peptide-drug conjugate, as a monotherapy aimed at treating patients with sortilin-positive recurrent advanced solid tumors resistant to standard therapies.
Moreover, in April 2024, Novartis, with its two marketed PDC drugs approved by the FDA, collaborated with PeptiDream to expand its peptide drug conjugate development collaboration in a deal valued at more than USD 2.8 billion.
Thus, the above-mentioned factors are expected to escalate the market of peptide drug conjugates in the region.
Peptide Drug Conjugates Market Key Players:
Some of the key market players operating in the peptide drug conjugates market include Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, and others.
Recent Developmental Activities in the Peptide Drug Conjugates Market:
Key Takeaways From the Peptide Drug Conjugates Market Report Study
Target Audience Who Can be Benefited From This Peptide Drug Conjugates Market Report Study
Frequently Asked Questions for the Peptide Drug Conjugates Market: